From: Regulation of autophagy by microRNAs in human breast cancer
Treatment types | Influence on treatment response | miRNA(s) | Autophagy activities ( ) | Proposed mechanisms/evidences | References |
---|---|---|---|---|---|
Chemotherapy | Resistant-promoting | miR-25 |
| miR-25 downregulated ULK1 to suppress autophagy and promote epirubicin resistance in breast cancer cells | [68] |
Sensitivity-promoting | miR-27a |
| miR-27a suppressed LC3-II and p62 expressions to inhibit autophagy and sensitized cancer cells to doxorubicin and paclitaxel | [82] | |
miR-129-5p |
| miR-129-5p suppressed HMGB1 to inhibit autophagy and sensitized breast cancer cells to taxol treatment | [61] | ||
miR-489 |
| miR-489 downregulated ULK1 to block autophagy and sensitized breast cancer cells to doxorubicin treatment | [37] | ||
Endocrine therapy | Resistant-promoting | miR-23b-3p |
| miR-23b-3p downregulated SLC6A14 to promote autophagy and tamoxifen resistance | [75] |
miR-21 |
| miR-21 could promote PI3K/AKT/mTOR pathway to inhibit autophagy and promote resistance towards both tamoxifen and fulvestrant | [35] | ||
Sensitivity-promoting | miR-101 |
| miR-101 suppressed ATG4D, STMN1 and RAB5A expressions to block autophagy and promote tamoxifen-induced cells death | [80] | |
Endocrine and chemotherapy | Sensitivity-promoting | miR-125b-5p |
| miR-125b-5p suppressed PAD2 expression to promote both autophagy and apoptosis. This sensitized cancer cells to both tamoxifen and docetaxel | [66] |
Radiotherapy | Sensitivity-promoting | miR-26b |
| miR-26b downregulated DRAM1 expression to inhibit autophagy and sensitize breast cancer cells to irradiation | [92] |
miR-200c |
| miR-200 downregulated UBQLN1 to block autophagy and sensitized breast cancer cells to irradiation | [93] | ||
Targeted therapy | Sensitivity-promoting | miR-567 |
| miR-567 suppressed autophagy by downregulating ATG5 to sensitize cancer cells to trastuzumab treatment | [78] |